American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research filed a joint Schedule 13G on November 16, 2026, disclosing beneficial ownership positions in Puma Biotechnology, Inc. (NASDAQ:PBYI) as of September 30, 2026.
Key Highlights
- American Century Investment Management, Inc. reported beneficial ownership of 2,742,653 shares, representing 5.3% of Puma Biotechnology's common stock.
- American Century ETF Trust reported separate beneficial ownership of 2,647,321 shares, representing 5.1% of the class.
- Sole voting and dispositive power is held entirely by each reporting person for their respective share counts, with no shared voting or dispositive power reported.
- American Century Companies, Inc. and Stowers Institute for Medical Research each reported the same 2,742,653 shares at 5.3%, reflecting their parent holding company and control person roles.
- American Century Investment Management, Inc. is described in the filing as a wholly-owned subsidiary of American Century Companies, Inc., which is controlled by the Stowers Institute for Medical Research.
- Event date triggering the filing was September 30, 2026.
American Century Entities Report Ownership Stakes in Puma Biotechnology Common Stock
According to the Schedule 13G filed November 16, 2026, four affiliated entities reported ownership of Puma Biotechnology, Inc. common stock as of September 30, 2026. American Century Investment Management, Inc. (ACIM), American Century Companies, Inc. (ACC), and Stowers Institute for Medical Research each disclosed beneficial ownership of 2,742,653 shares, equaling 5.3% of the class. American Century ETF Trust reported a separate position of 2,647,321 shares, equaling 5.1% of the class.
The filing states that ACIM is a wholly-owned subsidiary of ACC, which is controlled by the Stowers Institute for Medical Research. All four reporting persons are organized under the laws of Delaware and share a principal business address of 4500 Main Street, 9th Floor, Kansas City, Missouri 64111. Each reporting person disclosed zero shared voting power and zero shared dispositive power, with all voting and dispositive authority held on a sole basis.
The filing also discloses that "various persons, including the investment companies and separate institutional investor accounts that American Century Investment Management, Inc. serves as investment adviser, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities." The filing further states that no single client advised by ACIM owns more than 5% of the class. The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Four affiliated American Century entities filed a joint Schedule 13G reporting beneficial ownership in Puma Biotechnology common stock as of September 30, 2026, with ACIM, ACC, and Stowers each holding 2,742,653 shares (5.3%), and American Century ETF Trust holding 2,647,321 shares (5.1%).




Please wait processing your request...